
TREACE MEDICAL CONCEPTS INC
TMCINASDAQTrading Snapshot
- Day Range
- $4.44 โ $4.58
- 52-Week Range
- $1.17 โ $7.78
- Volume
- $3.28B
- Avg Volume
- $3.09B
- Shares Outstanding
- 64.9M
- Next Earnings
- Sep 25, 2026
Fundamentals Snapshot
- Annual Revenue
- $213M
- Last Q Revenue
- $45M
- P/E Ratio
- โ
- P/S Ratio
- 1.5x
- EPS (TTM)
- $-0.96
- Dividend Yield
- โ
Why Investors Own TMCI
- โHigh-growth profile โ revenue up +22.1% YoY with expanding US Equity exposure.
- โHealthy economics โ 30% gross margin and 26% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About TREACE MEDICAL CONCEPTS INC
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
Otter Score Breakdown
โAnalyst Ratings
โLatest News & Updates
Truist Securities Maintains Hold on Treace Medical Concepts, Raises Price Target to $5
Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and raises the price target from $4 to $5.

Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript
Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call August 7, 2026 8:00 AM EDTCompany ParticipantsTrip TaylorJohn Treace - Founder, Chairman &...

Treace Medical Concepts (NASDAQ:TMCI) Rises as Q2 Loss Narrows, Revenue Matches Estimates
Treace Medical Q2: Revenue $45.4M in line, EPS -$0.24 beats -$0.30 estimate. FY guidance raised, stock up 9% pre-market.
Treace Medical Concepts Q2 EPS $(0.24) Beats $(0.30) Estimate, Sales $45.376M Beat $44.020M Estimate
Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.30) by 20 percent. This is a 14.29 percent increase over losses of $(0.28) per share
Treace Medical Concepts Raises FY2026 Sales Guidance from $202.000M-$212.000M to $204.000M-$212.000M vs $206.220M Est
Treace Medical Concepts (NASDAQ:TMCI) raises FY2026 sales outlook from $202.000 million-$212.000 million to $204.000 million-$212.000 million vs $206.220 million estimate.
Truist Securities Maintains Hold on Treace Medical Concepts, Raises Price Target to $4
Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and raises the price target from $2 to $4.